N. Matsumoto

发表

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC

Daisuke Ishikawa, Hiroshi Tanaka, Kosuke Ichikawa, 2022, Scientific reports.

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events

Kazuhiro Sato, Hiroshi Tanaka, Aya Ohtsubo, 2021, Frontiers in Oncology.

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases

Kazuhiro Sato, T. Ishida, Hiroshi Tanaka, 2019, Thoracic cancer.

Lymph Nodes in the Presence of Apoptotic Potent Antitumor CD4+ T Cells in Draining CD40 Ligand Promotes Priming of Fully

F. Gejyo, E. Suzuki, H. Kagamu, 2013 .

CD40 Ligand Promotes Priming of Fully Potent Antitumor CD4+ T Cells in Draining Lymph Nodes in the Presence of Apoptotic Tumor Cells

H. Hamada, F. Gejyo, E. Suzuki, 2001, The Journal of Immunology.

Tumor Cells Lymph Nodes in the Presence of Apoptotic T Cells in Draining + Potent Antitumor CD4 CD40 Ligand Promotes Priming of Fully

H. Hamada, F. Gejyo, E. Suzuki, 2001 .

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC

Daisuke Ishikawa, Hiroshi Tanaka, Kosuke Ichikawa, 2021, Scientific reports.

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)

K. Nishio, Daisuke Ishikawa, T. Sekiya, 2022, Cancers.

A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401)

Kazuhiro Sato, T. Ishida, Hiroshi Tanaka, 2021, Translational lung cancer research.

Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients

Aya Ohtsubo, Kosuke Ichikawa, T. Kikuchi, 2021, Translational lung cancer research.